LAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Standard BioTools Inc (LAB) is not a strong buy for a beginner investor with a long-term strategy at this time. The company's weak financial performance, lack of significant positive trading trends, and bearish technical indicators suggest limited upside potential in the near term. While the stock shows some potential for a rebound in the next month, the overall sentiment and financial health do not align with the user's investment goals.
The MACD is slightly positive and expanding, but the RSI is neutral, indicating no clear momentum. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its pivot level of 1.162 with resistance at 1.22 and support at 1.105. These indicators suggest a weak technical setup.
The company has consistently beaten revenue estimates in the past and reported preliminary revenue of $85 million for 2025, exceeding estimates.
The upcoming Q4 earnings report is expected to show a revenue decline, which could lead to negative market reactions. Additionally, the company's financials for Q4 2025 show significant YoY declines in revenue (-49.07%), net income (-156.59%), and EPS (-155.56%).
The company's Q4 2025 financials are weak, with substantial declines in revenue, net income, and EPS. However, gross margin improved slightly to 47.83%, up 2.00% YoY.
No recent analyst rating or price target changes are available. Wall Street sentiment appears neutral, with no significant pros or cons highlighted.
